---
title: '3-year invasive disease-free survival with chemotherapy de-escalation using
  an <sup>18</sup>F-FDG-PET-based, pathological complete response-adapted strategy
  in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase
  2 trial'
date: '2024-04-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38582092/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240407180650&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: PHERGain was designed to assess the feasibility, safety,
  and efficacy of a chemotherapy-free treatment based on a dual human epidermal growth
  factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab in patients with
  HER2-positive early breast cancer (EBC). It used an ^(18)fluorine-fluorodeoxyglucose-PET-based,
  pathological complete response (pCR)-adapted ...'
disable_comments: true
---
BACKGROUND: PHERGain was designed to assess the feasibility, safety, and efficacy of a chemotherapy-free treatment based on a dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer (EBC). It used an ^(18)fluorine-fluorodeoxyglucose-PET-based, pathological complete response (pCR)-adapted ...